← All Gsk PLC filings

Gsk PLC Schedule 13D activist filings

Filed when an investor crosses five percent and intends to influence the company — the activist disclosure.

NYSE
GSK
Gsk PLC
SCHEDULE: GSK Exits CureVac, Divests All Common Shares
GSK plc has completed the divestment of its entire stake in CureVac N.V. through a tender offer, ceasing to be a beneficial owner.
NYSE
GSK
Gsk PLC
SCHEDULE: GSK to Tender CureVac Shares in BioNTech Offer
GSK plc's subsidiary, Glaxo Group Limited, has agreed to tender its 7.4% stake in CureVac N.V. into BioNTech SE's exchange offer.
NYSE
GSK
Gsk PLC
SCHEDULE 13D/A: GSK PLC Amends Spero Therapeutics Stake, Ownership Percentage Decreases to 16.4%
GSK PLC has filed an Amendment No. 9 to its Schedule 13D, reporting a decrease in its beneficial ownership of Spero Therapeutics, Inc. common stock to 16.4% due to an increase in Spero's outstanding shares.